Home›Companies›Healthcare›Glycotest

Glycotest Inc.

Develops blood tests to help physicians detect liver cancer in at-risk patients.

Updated Nov 10, 2026·Latest SEC filing Jul 16, 2026·Suggest an edit

About Glycotest

Glycotest is a private company based in Merion Station, Pennsylvania. It has reported $3,220,105 raised in one offering on Form D since July 2026. Its chief executive is Charles Swindell.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 30, 2026Jul 16, 2026$3,220,105of $6.7M target3$1.0MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Glycotest's Form D filed Jul 16, 2026.

JJ
Jenny Jiang
Director
Ilian Iliev
Ilian Iliev
Board Chair
Ed Hooper
Ed Hooper
Board Member
Charles Swindell
Charles Swindell
CEO and Board Member

Sources

  1. SECGlycotest Inc. filing history
  2. CompanyContact
  3. CompanyAbout Glycotest
  4. CompanyLeadership and Shareholders